Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

Blood

Volumn 123, Issue 9, 2014, Pages 1372-1383

  Marty, Caroline ^a,b   Saint Martin, Cécile ^a,c   Pecquet, Christian ^d,e   Grosjean, Sarah ^a,c   Saliba, Joseph ^a,b   Mouton, Céline ^d,e   Leroy, Emilie ^d,e   Harutyunyan, Ashot S ^f   Abgrall, Jean François ^g   Favier, Rémi ^a,h   Toussaint, Aurélie ⁱ   Solary, Eric ^a,b   Kralovics, Robert ^f,j   Constantinescu, Stefan N ^d,e   Najman, Albert ^k   Vainchenker, William ^a,b   Plo, Isabelle ^a,b   Bellanné Chantelot, Christine ^a,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^e DE DUVE INSTITUTE   (Belgium)

^f ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^g BREST UNIVERSITY HOSPITAL   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ université Paris Cité   (France)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; JANUS KINASE 2; STAT1 PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; JAK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; EXON; FAMILY; GAIN OF FUNCTION MUTATION; GERM LINE; GERMLINE MUTATION; HETEROZYGOTE; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTOSIS; WESTERN BLOTTING; ADOLESCENT; ADULT; AGED; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PROTEIN TERTIARY STRUCTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; CELLS, CULTURED; DRUG RESISTANCE; FEMALE; GERM-LINE MUTATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; JANUS KINASE 2; MALE; MICE; MIDDLE AGED; PEDIGREE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; THROMBOCYTOSIS; YOUNG ADULT;

EID: 84899696697     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-504555     Document Type: Article

References (32)

1. Chang Y, Bluteau D, Debili N, Vainchenker W. From hematopoietic stem cells to platelets. J Thromb Haemost. 2007;5(suppl 1):318-327. (Pubitemid 46958849)
2. Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009(1):159-167.
3. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352. (Pubitemid 43990648)
4. Saint-Martin C, Leroy G, Delhommeau F, et al French Group of Familial Myeloproliferative Disorders. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628-1632.
5. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141-149.
6. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200. (Pubitemid 38685363)
7. El-Harith EA, Roesl C, Ballmaier M, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185-194.
8. Vilaine M, Gourain V, Cleyrat C, et al. Germline MPLW515R mutation in a family with isolated thrombocytosis [abstract]. Blood. 2012;120(21). Abstract 1764.
9. Etheridge L, Corbo LM, Kaushansky K, Chan E, Hitchcock IS. A novel activating JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis (fET) via mechanisms distinct from JAK2V617F [abstract]. Blood. 2011;118(21). Abstract 123.
10. Mead AJ, Chowdhury O, Pecquet C, et al. Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood. 2013;121(20):4156-4165.
11. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967-969.
12. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood. 1999;94(4):1480-1482. (Pubitemid 29380432)
13. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol. 1999;107(2):310-316. (Pubitemid 29530216)
14. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood. 1998;92(4):1091-1096. (Pubitemid 28369020)
15. Wiestner A, Padosch SA, Ghilardi N, et al. Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol. 2000;110(1):104-109. (Pubitemid 30627498)
16. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
17. Debili N, Coulombel L, Croisille L, et al. Characterization of a bipotent erythromegakaryocytic progenitor in human bone marrow. Blood. 1996;88(4):1284-1296. (Pubitemid 26276803)
18. Norol F, Vitrat N, Cramer E, et al. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Blood. 1998;91(3):830-843. (Pubitemid 28078285)
19. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
20. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107(1):176-183. (Pubitemid 43053540)
21. Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol. 2012;19(8):754-759.
22. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell. 2003;14(4):1448-1459. (Pubitemid 36547413)
23. Bertelsen B, Tümer Z, Ravn K. Three new loci for determining X chromosome inactivation patterns. J Mol Diagn. 2011;13(5):537-540.
24. Besancenot R, Chaligné R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol. 2010;8(9):e1000476.
25. Pecquet C, Diaconu CC, Staerk J, et al. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood. 2012;119(20):4625-4635.
26. Staerk J, Defour JP, Pecquet C, et al. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J. 2011;30(21):4398-4413.
27. Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012;26(4):708-715.
28. Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209(2):259-273.
29. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106(23):9414-9418.
30. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280(29):27251-27261. (Pubitemid 41040765)
31. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-535.
32. Hornakova T, Springuel L, Devreux J, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica. 2011;96(6):845-853.